Sarepta Therapeutics, Inc. SRPT
- SRP-1001 — Facioscapulohumeral Muscular Dystrophy Phase 1
- SRP-1003 — Myotonic Dystrophy Type 1 Phase 1
Home › Targets › αvβ6 Integrin
αvβ6 Integrin (1 companies · 2 programs)
Companies with an active program directed at αvβ6 Integrin.